Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Anemia | Research

Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study

Authors: Lois Lamerato, Glen James, Heleen van Haalen, Katarina Hedman, James A. Sloand, Amy Tang, Eric T. Wittbrodt, Jerry Yee

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Optimal management of anemia of chronic kidney disease (CKD) remains controversial. This retrospective study aimed to describe the epidemiology and selected clinical outcomes of anemia in patients with CKD in the US.

Methods

Data were extracted from Henry Ford Health System databases. Adults with stages 3a–5 CKD not on dialysis (estimated glomerular filtration rate < 60 mL/min/1.73m2) between January 1, 2013 and December 31, 2017 were identified. Patients on renal replacement therapy or with active cancer or bleeding were excluded. Patients were followed for ≥12 months until December 31, 2018. Outcomes included incidence rates per 100 person-years (PY) of anemia (hemoglobin < 10 g/dL), renal and major adverse cardiovascular events, and of bleeding and hospitalization outcomes. Adjusted Cox proportional hazards models identified factors associated with outcomes after 1 and 5 years.

Results

Among the study cohort (N = 50,701), prevalence of anemia at baseline was 23.0%. Treatments used by these patients included erythropoiesis-stimulating agents (4.1%), iron replacement (24.2%), and red blood cell transfusions (11.0%). Anemia incidence rates per 100 PY in patients without baseline anemia were 7.4 and 9.7 after 1 and 5 years, respectively. Baseline anemia was associated with increased risk of renal and major cardiovascular events, hospitalizations (all-cause and for bleeding), and transfusion requirements. Increasing CKD stage was associated with increased risk of incident anemia, renal and major adverse cardiovascular events, and hospitalizations.

Conclusions

Anemia was a prevalent condition associated with adverse renal, cardiovascular, and bleeding/hospitalization outcomes in US patients with CKD. Anemia treatment was infrequent.
Appendix
Available only for authorised users
Literature
1.
go back to reference St Peter WL, Guo H, Kabadi S, Gilbertson DT, Peng Y, Pendergraft T, et al. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol. 2018;19(1):67.CrossRef St Peter WL, Guo H, Kabadi S, Gilbertson DT, Peng Y, Pendergraft T, et al. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol. 2018;19(1):67.CrossRef
2.
go back to reference Finkelstein FO, Finkelstein SH. The impact of anemia treatment on health-related quality of life in patients with chronic kidney disease in the contemporary era. Adv Chronic Kidney Dis. 2019;26(4):250–2.CrossRef Finkelstein FO, Finkelstein SH. The impact of anemia treatment on health-related quality of life in patients with chronic kidney disease in the contemporary era. Adv Chronic Kidney Dis. 2019;26(4):250–2.CrossRef
3.
go back to reference Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631–4.CrossRef Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631–4.CrossRef
4.
go back to reference Toft G, Heide-Jorgensen U, van Haalen H, James G, Hedman K, Birn H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J Nephrol. 2020;33(1):147–56.CrossRef Toft G, Heide-Jorgensen U, van Haalen H, James G, Hedman K, Birn H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J Nephrol. 2020;33(1):147–56.CrossRef
5.
go back to reference van Nooten FE, Green J, Brown R, Finkelstein FO, Wish J. Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature. J Med Econ. 2010;13(2):241–56.CrossRef van Nooten FE, Green J, Brown R, Finkelstein FO, Wish J. Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature. J Med Econ. 2010;13(2):241–56.CrossRef
6.
go back to reference Pergola PE, Pecoits-Filho R, Winkelmayer WC, Spinowitz B, Rochette S, Thompson-Leduc P, et al. Economic burden and health-related quality of life associated with current treatments for anaemia in patients with CKD not on dialysis: a systematic review. Pharmacoecon Open. 2019;3(4):463–78.CrossRef Pergola PE, Pecoits-Filho R, Winkelmayer WC, Spinowitz B, Rochette S, Thompson-Leduc P, et al. Economic burden and health-related quality of life associated with current treatments for anaemia in patients with CKD not on dialysis: a systematic review. Pharmacoecon Open. 2019;3(4):463–78.CrossRef
7.
go back to reference Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.CrossRef Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.CrossRef
8.
go back to reference Ryu SR, Park SK, Jung JY, Kim YH, Oh YK, Yoo TH, et al. The prevalence and management of anemia in chronic kidney disease patients: result from the KoreaN cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD). J Korean Med Sci. 2017;32(2):249–56.CrossRef Ryu SR, Park SK, Jung JY, Kim YH, Oh YK, Yoo TH, et al. The prevalence and management of anemia in chronic kidney disease patients: result from the KoreaN cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD). J Korean Med Sci. 2017;32(2):249–56.CrossRef
9.
go back to reference Vestergaard SV, Heide-Jorgensen U, van Haalen H, James G, Hedman K, Birn H, et al. Risk of anemia in patients with newly identified chronic kidney disease - a population-based cohort study. Clin Epidemiol. 2020;12:953–62.CrossRef Vestergaard SV, Heide-Jorgensen U, van Haalen H, James G, Hedman K, Birn H, et al. Risk of anemia in patients with newly identified chronic kidney disease - a population-based cohort study. Clin Epidemiol. 2020;12:953–62.CrossRef
10.
go back to reference Coyne DW, Goldsmith D, Macdougall IC. New options for the anemia of chronic kidney disease. Kidney Int Suppl (2011). 2017;7(3):157–63.CrossRef Coyne DW, Goldsmith D, Macdougall IC. New options for the anemia of chronic kidney disease. Kidney Int Suppl (2011). 2017;7(3):157–63.CrossRef
11.
go back to reference Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, et al. Anemia and iron deficiency among chronic kidney disease stages 3–5ND patients in the chronic kidney disease outcomes and practice patterns study: often unmeasured, variably treated. Clin Kidney J. 2019;13(4):613–24.CrossRef Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, et al. Anemia and iron deficiency among chronic kidney disease stages 3–5ND patients in the chronic kidney disease outcomes and practice patterns study: often unmeasured, variably treated. Clin Kidney J. 2019;13(4):613–24.CrossRef
13.
go back to reference Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65(3):757–67.CrossRef Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65(3):757–67.CrossRef
14.
go back to reference Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.CrossRef Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.CrossRef
15.
go back to reference Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.CrossRef Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.CrossRef
16.
go back to reference Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.CrossRef Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.CrossRef
17.
go back to reference Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (London, England). 2007;369(9559):381–8. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (London, England). 2007;369(9559):381–8.
19.
go back to reference Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–59.CrossRef Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–59.CrossRef
20.
go back to reference Park H, Liu X, Henry L, Harman J, Ross EA. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015). BMC Nephrol. 2018;19(1):318.CrossRef Park H, Liu X, Henry L, Harman J, Ross EA. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015). BMC Nephrol. 2018;19(1):318.CrossRef
21.
go back to reference Stirnadel-Farrant HA, Luo J, Kler L, Cizman B, Jones D, Brunelli SM, et al. Anemia and mortality in patients with nondialysis-dependent chronic kidney disease. BMC Nephrol. 2018;19(1):135.CrossRef Stirnadel-Farrant HA, Luo J, Kler L, Cizman B, Jones D, Brunelli SM, et al. Anemia and mortality in patients with nondialysis-dependent chronic kidney disease. BMC Nephrol. 2018;19(1):135.CrossRef
22.
go back to reference Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM, et al. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Sci Rep. 2021;11(1):1784.CrossRef Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM, et al. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Sci Rep. 2021;11(1):1784.CrossRef
23.
go back to reference Lawler EV, Bradbury BD, Fonda JR, Gaziano JM, Gagnon DR. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol. 2010;5(4):667–72.CrossRef Lawler EV, Bradbury BD, Fonda JR, Gaziano JM, Gagnon DR. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol. 2010;5(4):667–72.CrossRef
24.
go back to reference Lamerato L, Wittbrodt E, Kaur M, Datto C, Singla S. Impact of opioid use on patients undergoing screening colonoscopy according to the quality of bowel preparation. JGH Open. 2019;4:490–6.CrossRef Lamerato L, Wittbrodt E, Kaur M, Datto C, Singla S. Impact of opioid use on patients undergoing screening colonoscopy according to the quality of bowel preparation. JGH Open. 2019;4:490–6.CrossRef
25.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRef Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRef
26.
go back to reference Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
27.
go back to reference Li Y, Shi H, Wang WM, Peng A, Jiang GR, Zhang JY, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine (Baltimore). 2016;95(24):e3872.CrossRef Li Y, Shi H, Wang WM, Peng A, Jiang GR, Zhang JY, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine (Baltimore). 2016;95(24):e3872.CrossRef
28.
go back to reference Stack AG, Alghali A, Li X, Ferguson JP, Casserly LF, Cronin CJ, et al. Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. Clin Kidney J. 2018;11(1):99–107.CrossRef Stack AG, Alghali A, Li X, Ferguson JP, Casserly LF, Cronin CJ, et al. Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. Clin Kidney J. 2018;11(1):99–107.CrossRef
29.
go back to reference Minutolo R, Locatelli F, Gallieni M, Bonofiglio R, Fuiano G, Oldrizzi L, et al. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant. 2013;28(12):3035–45.CrossRef Minutolo R, Locatelli F, Gallieni M, Bonofiglio R, Fuiano G, Oldrizzi L, et al. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant. 2013;28(12):3035–45.CrossRef
30.
go back to reference Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, et al. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with Aranesp therapy (TREAT). Am J Kidney Dis. 2019;73(3):309–15.CrossRef Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, et al. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with Aranesp therapy (TREAT). Am J Kidney Dis. 2019;73(3):309–15.CrossRef
31.
go back to reference Wetmore JB, Li S, Yan H, Xu H, Peng Y, Sinsakul MV, et al. Predialysis anemia management and outcomes following dialysis initiation: a retrospective cohort analysis. PLoS One. 2018;13(9):e0203767.CrossRef Wetmore JB, Li S, Yan H, Xu H, Peng Y, Sinsakul MV, et al. Predialysis anemia management and outcomes following dialysis initiation: a retrospective cohort analysis. PLoS One. 2018;13(9):e0203767.CrossRef
32.
go back to reference Fishbane S, Ross DW, Hong S. Anemia in non–dialysis-dependent CKD: to treat or not to treat? Am J Kidney Dis. 2019;73(3):297–9.CrossRef Fishbane S, Ross DW, Hong S. Anemia in non–dialysis-dependent CKD: to treat or not to treat? Am J Kidney Dis. 2019;73(3):297–9.CrossRef
33.
go back to reference Stirnadel-Farrant HA, Karaboyas A, Cizman B, Bieber BA, Kler L, Jones D, et al. Cardiovascular event rates among hemodialysis patients across geographical regions-a snapshot from the dialysis outcomes and practice patterns study (DOPPS). Kidney Int Rep. 2019;4(6):864–72.CrossRef Stirnadel-Farrant HA, Karaboyas A, Cizman B, Bieber BA, Kler L, Jones D, et al. Cardiovascular event rates among hemodialysis patients across geographical regions-a snapshot from the dialysis outcomes and practice patterns study (DOPPS). Kidney Int Rep. 2019;4(6):864–72.CrossRef
34.
go back to reference Wetmore JB, Li S, Ton TGN, Peng Y, Hansen MK, Neslusan C, et al. Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study. BMC Endocr Disord. 2019;19(1):89.CrossRef Wetmore JB, Li S, Ton TGN, Peng Y, Hansen MK, Neslusan C, et al. Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study. BMC Endocr Disord. 2019;19(1):89.CrossRef
35.
go back to reference Iimori S, Naito S, Noda Y, Nishida H, Kihira H, Yui N, et al. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: the CKD-ROUTE study. Nephrology (Carlton, Vic). 2015;20(9):601–8.CrossRef Iimori S, Naito S, Noda Y, Nishida H, Kihira H, Yui N, et al. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: the CKD-ROUTE study. Nephrology (Carlton, Vic). 2015;20(9):601–8.CrossRef
36.
go back to reference Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes-a systematic literature review. Int J Nephrol. 2020;2020:7692376.CrossRef Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes-a systematic literature review. Int J Nephrol. 2020;2020:7692376.CrossRef
37.
go back to reference Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1082–8.CrossRef Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1082–8.CrossRef
38.
go back to reference Liu M, Ning X, Li R, Yang Z, Yang X, Sun S, et al. Signalling pathways involved in hypoxia-induced renal fibrosis. J Cell Mol Med. 2017;21(7):1248–59.CrossRef Liu M, Ning X, Li R, Yang Z, Yang X, Sun S, et al. Signalling pathways involved in hypoxia-induced renal fibrosis. J Cell Mol Med. 2017;21(7):1248–59.CrossRef
39.
go back to reference Eckardt KU. Anaemia in end-stage renal disease: pathophysiological considerations. Nephrol Dial Transplant. 2001;16(Suppl 7):2–8.CrossRef Eckardt KU. Anaemia in end-stage renal disease: pathophysiological considerations. Nephrol Dial Transplant. 2001;16(Suppl 7):2–8.CrossRef
40.
go back to reference Hounkpatin HO, Fraser SDS, Honney R, Dreyer G, Brettle A, Roderick PJ. Ethnic minority disparities in progression and mortality of pre-dialysis chronic kidney disease: a systematic scoping review. BMC Nephrol. 2020;21(1):217.CrossRef Hounkpatin HO, Fraser SDS, Honney R, Dreyer G, Brettle A, Roderick PJ. Ethnic minority disparities in progression and mortality of pre-dialysis chronic kidney disease: a systematic scoping review. BMC Nephrol. 2020;21(1):217.CrossRef
Metadata
Title
Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study
Authors
Lois Lamerato
Glen James
Heleen van Haalen
Katarina Hedman
James A. Sloand
Amy Tang
Eric T. Wittbrodt
Jerry Yee
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02778-8

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue